Cargando…

Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors

Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still low. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zellmer, Johannes, Yen, Hsi-Yu, Kaiser, Lena, Gildehaus, Franz Josef, Böning, Guido, Steiger, Katja, Hacker, Marcus, Bartenstein, Peter, Todica, Andrei, Haug, Alexander R., Ilhan, Harun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775670/
https://www.ncbi.nlm.nih.gov/pubmed/36551858
http://dx.doi.org/10.3390/biomedicines10123102
_version_ 1784855701529559040
author Zellmer, Johannes
Yen, Hsi-Yu
Kaiser, Lena
Gildehaus, Franz Josef
Böning, Guido
Steiger, Katja
Hacker, Marcus
Bartenstein, Peter
Todica, Andrei
Haug, Alexander R.
Ilhan, Harun
author_facet Zellmer, Johannes
Yen, Hsi-Yu
Kaiser, Lena
Gildehaus, Franz Josef
Böning, Guido
Steiger, Katja
Hacker, Marcus
Bartenstein, Peter
Todica, Andrei
Haug, Alexander R.
Ilhan, Harun
author_sort Zellmer, Johannes
collection PubMed
description Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still low. In this study, we investigated the synergistic and potentially enhanced efficacy of a combined treatment with everolimus and [177Lu]Lu-DOTA-TATE in a mouse model. Baseline [68Ga]Ga-DOTA-TATE PET scans were obtained five days after athymic CD1 mice were inoculated with AR42J tumor cells, before separating the animals into four groups. Group 1 received a placebo, group 2 everolimus, group 3 a placebo and PRRT, and group 4 everolimus and PRRT. The treatment response was monitored by manually measuring the tumor volumes (manual tumor volume, MTV) and conducting sequential [68Ga]Ga-DOTA-TATE PET scans at one, two, and four weeks after treatment induction. The biological tumor volume (BTV) was derived from PET scans using threshold-based volume of interest (VOI) measurements. Tracer uptake was measured semi-quantitatively as a tumor to background ratio (TBR). Mice were euthanized due to excessive tumor growth according to the ethics protocol; blood samples were drawn for the preparation of full blood counts and kidneys were obtained for histological analysis. For the histological assessment, a standardized score (renal damage score, RDS) was used. Full blood counts showed significantly increased numbers of neutrophils and lymphocytes in the groups receiving PRRT. All other parameters did not differ relevantly. In the histological analysis, groups receiving PRRT had a significantly higher RDS, whereas everolimus only tended to cause an increase in the RDS. Mice in groups 1 and 2 had to be euthanized due to excessive tumor growth two weeks after the start of the therapy, whereas follow-up in groups 3 and 4 comprised four weeks. PRRT significantly inhibited tumor growth; the administration of everolimus did not induce an additional effect. A good correlation existed between MTV and BTV. PRRT significantly reduced the TBR. [68Ga]Ga-DOTA-TATE PET is suitable for monitoring tumor growth in the applied model. The high efficacy of [177Lu]Lu-DOTA-TATE is not enhanced by the combination with everolimus.
format Online
Article
Text
id pubmed-9775670
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97756702022-12-23 Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors Zellmer, Johannes Yen, Hsi-Yu Kaiser, Lena Gildehaus, Franz Josef Böning, Guido Steiger, Katja Hacker, Marcus Bartenstein, Peter Todica, Andrei Haug, Alexander R. Ilhan, Harun Biomedicines Article Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still low. In this study, we investigated the synergistic and potentially enhanced efficacy of a combined treatment with everolimus and [177Lu]Lu-DOTA-TATE in a mouse model. Baseline [68Ga]Ga-DOTA-TATE PET scans were obtained five days after athymic CD1 mice were inoculated with AR42J tumor cells, before separating the animals into four groups. Group 1 received a placebo, group 2 everolimus, group 3 a placebo and PRRT, and group 4 everolimus and PRRT. The treatment response was monitored by manually measuring the tumor volumes (manual tumor volume, MTV) and conducting sequential [68Ga]Ga-DOTA-TATE PET scans at one, two, and four weeks after treatment induction. The biological tumor volume (BTV) was derived from PET scans using threshold-based volume of interest (VOI) measurements. Tracer uptake was measured semi-quantitatively as a tumor to background ratio (TBR). Mice were euthanized due to excessive tumor growth according to the ethics protocol; blood samples were drawn for the preparation of full blood counts and kidneys were obtained for histological analysis. For the histological assessment, a standardized score (renal damage score, RDS) was used. Full blood counts showed significantly increased numbers of neutrophils and lymphocytes in the groups receiving PRRT. All other parameters did not differ relevantly. In the histological analysis, groups receiving PRRT had a significantly higher RDS, whereas everolimus only tended to cause an increase in the RDS. Mice in groups 1 and 2 had to be euthanized due to excessive tumor growth two weeks after the start of the therapy, whereas follow-up in groups 3 and 4 comprised four weeks. PRRT significantly inhibited tumor growth; the administration of everolimus did not induce an additional effect. A good correlation existed between MTV and BTV. PRRT significantly reduced the TBR. [68Ga]Ga-DOTA-TATE PET is suitable for monitoring tumor growth in the applied model. The high efficacy of [177Lu]Lu-DOTA-TATE is not enhanced by the combination with everolimus. MDPI 2022-12-01 /pmc/articles/PMC9775670/ /pubmed/36551858 http://dx.doi.org/10.3390/biomedicines10123102 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zellmer, Johannes
Yen, Hsi-Yu
Kaiser, Lena
Gildehaus, Franz Josef
Böning, Guido
Steiger, Katja
Hacker, Marcus
Bartenstein, Peter
Todica, Andrei
Haug, Alexander R.
Ilhan, Harun
Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
title Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
title_full Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
title_fullStr Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
title_full_unstemmed Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
title_short Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
title_sort evaluation of the efficacy of a combined treatment using the mtor-inhibitor everolimus and [177lu]lu-dota-tate in nude cd1 mice with sstr-expressing pancreatic ar42j xenograft tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775670/
https://www.ncbi.nlm.nih.gov/pubmed/36551858
http://dx.doi.org/10.3390/biomedicines10123102
work_keys_str_mv AT zellmerjohannes evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT yenhsiyu evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT kaiserlena evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT gildehausfranzjosef evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT boningguido evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT steigerkatja evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT hackermarcus evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT bartensteinpeter evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT todicaandrei evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT haugalexanderr evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors
AT ilhanharun evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors